How much does OPDIVO (Nivolumab Injection) Cost& price without insurance in China?
OPDIVO® is the commercial brand name of Nivolumab Injection, a fully human anti-PD-1 monoclonal antibody developed by Bristol Myers Squibb. It blocks the binding of PD-1 receptor to its ligands PD-L1 and PD-L2, restoring the anti-tumor immune activity of T lymphocytes.
Main Indications
Treatment of unresectable advanced or metastatic melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, urothelial carcinoma and multiple other advanced solid tumors after failure of prior systemic therapies.
First-line combination treatment for a variety of advanced malignant tumors.
Common Side Effects
Common mild adverse reactions: Fatigue, fever, rash, pruritus, hypothyroidism and infusion-related reactions.
Laboratory abnormalities: Decreased lymphocyte count, abnormal thyroid function and elevated liver enzymes.
Severe but uncommon risks: Immune-related pneumonitis, immune-related hepatitis, severe immune enterocolitis, and severe endocrine immune adverse events.
Approval Status in China
OPDIVO® (Nivolumab Injection, 100mg/10mL) was officially approved for marketing in China in 2018. It is currently a prescription anti-tumor drug included in China’s Category B medical insurance.
Buy OPDIVO (Nivolumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
